Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omacetaxine mepesuccinate - Teva Pharmaceutical Industries

Next Previous
X
Search
Drug Profile

Omacetaxine mepesuccinate - Teva Pharmaceutical Industries

Alternative Names: C41443; Ceflatonin®; CGX-635; CXS-635; HHT; Homoharringtonine; Homoharringtonine-ChemGenex; NCI 141633; Omapro™; Synribo

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChemGenex Pharmaceuticals; Stragen Pharma SA
  • Developer ChemGenex Pharmaceuticals; Roswell Park Cancer Institute; Teva Pharmaceutical Industries; University of Hong Kong; University of Texas M. D. Anderson Cancer Center
  • Class Alkaloids; Antineoplastics; Harringtonines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin D1 inhibitors; MCL1 protein inhibitors; Protein synthesis inhibitors; Proto-oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported Haematological malignancies
  • Discontinued Acute promyelocytic leukaemia; Solid tumours

Most Recent Events

  • 21 Feb 2021 Omacetaxine mepesuccinate is still in phase II trials for Acute myeloid leukaemia in Hong Kong (NCT03135054) (NDR batch 18)
  • 10 Dec 2020 University of Hong Kong completes enrolment in a phase II trial in Acute myeloid leukaemia (Newly diagnosed, Second-line therapy or greater, Combination therapy) in HongKong (NCT03135054)
  • 14 Apr 2020 M.D. Anderson Cancer Center and Teva Pharmaceuticals completes the phase II trial in myelodysplastic syndrome in USA (SC) (NCT02159872)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top